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Abstract
Background: Routine tuberculosis culture remains unavailable in many high-burden areas, including Tanzania. This
study sought to determine the impact of providing mycobacterial culture results over standard of care [unconcentrated
acid-fast (AFB) smears] on management of persons with suspected tuberculosis.
Methods: Adults and children with suspected tuberculosis were randomized to standard (direct AFB smear only) or
intensified (concentrated AFB smear and tuberculosis culture) diagnostics and followed for 8 weeks. The primary
endpoint was appropriate treatment (i.e. antituberculosis therapy for those with tuberculosis, no antituberculous
therapy for those without tuberculosis).
Results: Seventy participants were randomized to standard (n = 37, 53%) or intensive (n = 33, 47%) diagnostics. At
8 weeks, 100% (n = 22) of participants in follow up randomized to intensive diagnostics were receiving appropriate
care, vs. 22 (88%) of 25 participants randomized to standard diagnostics (p = 0.14). Overall, 18 (26%) participants died;
antituberculosis therapy was associated with lower mortality (9% who received antiuberculosis treatment died vs. 26%
who did not, p = 0.04).
Conclusions: Under field conditions in a high burden setting, the impact of intensified diagnostics was blunted by high
early mortality. Enhanced availability of rapid diagnostics must be linked to earlier access to care for outcomes to improve.
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Background
Tuberculosis remains a major worldwide public health
problem, and difficulties in tuberculosis (TB) diagnosis
have stalled progress in reducing the burden of disease,
especially in endemic areas [1-3]. Tanzania ranks 18th
among the 22 countries with the highest burden of TB
worldwide [1], with an estimated incidence of TB of 312
cases/100,000 persons/year in 2007 at the time this re-
search was initiated [4]. Unconcentrated sputum smear
and symptomatology for smear-negative patients remain
the mainstay of diagnosis [1,3,5-10], with bacterial cul-
ture limited by cost, infrastructure, and availability of
trained personnel [11-13].
While availability of culture is assumed to improve
management of tuberculosis in resource-limited settings,
the degree to which availability of tuberculosis culture
results change management decisions and clinical out-
comes in a setting where clinical diagnosis is the norm
has never been documented systematically. Early death
[14-16], loss to follow up after initial sputum testing
[14,17], and clinicians’ reluctance to exclude a diagnosis of
tuberculosis even with a negative culture all may lessen
the impact of tuberculosis culture results [18]. Carefully
documenting the outcomes of patients followed with trad-
itional (smear only) versus intensified (concentrated smear
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plus culture) diagnostic strategies would offer important
information about prioritization and optimal implementa-
tion of tuberculosis diagnostics.
To address these questions, we conducted a random-
ized trial in Northern Tanzania of standard (acid fast
bacilli (AFB) smear of gastric aspirate (GA) or sputum
alone) or intensified (concentrated AFB smear and cul-
ture) diagnostics.
Methods
Study design and setting
This was a non-blinded individually randomized clin-
ical trial. Subjects were recruited between November
2008 and July 2009 from Kilimanjaro Christian Medical
Centre (KCMC), a 458 bed referral hospital for northern
Tanzania, and Mawenzi Regional Hospital, a 300 bed
regional hospital; both hospitals are located in Moshi,
population ≈ 144,000 [19]. All inpatients were screened for
inclusion; outpatients could also be referred to the study.
Inclusion criteria
Adults (defined for the purposes of analysis as ≥6 years
of age based on the unique characteristics of TB in
younger versus older children and adults) and children
(<6 years) were eligible for inclusion if they resided in
the Kilimanjaro region with no plans to move during the
study and consented to HIV testing. All potential sub-
jects had to have 2 weeks of cough (and/or difficulty
breathing for children) plus at least one of the following:
recurrent fever, weight loss, night sweats, hemoptysis,
failure to thrive (for children only), household contact
with known/suspected tuberculosis (for children only),
or a chest radiograph suspicious for tuberculosis. In
addition, adult participants had to be able to provide at
least one sputum specimen for testing.
Study procedures
All patients (for participants ≥18 years of age) or their par-
ent or guardian (for participants <18 years of age) pro-
vided written informed consent; assent was also required
for participants aged 12 and older. Thereafter, a research
questionnaire was completed and blood was drawn for
HIV-1 antibody testing. CD4-positive T-lymphocyte cell
count (CD4 count) and CD4 percentage were performed
in the case of HIV-1 antibody positivity and HIV-1 anti-
body positivity was confirmed with HIV RNA in children
≤18 months of age. One sputum specimen was collected
from all patients able to expectorate at the time of
enrollment, with subsequent specimens collected the
following 2 mornings for hospitalized patients or the
following morning for outpatients. Therefore, a total of
3 samples were collected from hospitalized adults and a
total of 2 samples were collected from outpatients; this
was because of transportation challenges in requiring
outpatients to return specimens. Children < 6 years of
age who were not able to expectorate were hospitalized
and 3 fasting GA samples were collected into specimen
containers prefilled with 100 mg of sodium bicarbonate.
Tuberculin skin tests (TST; Mantoux method using 5
TU of tuberculin) were placed by trained study personnel
and read 48–72 hours later, with 5 mm of induration con-
sidered reactive for HIV-infected participants and 10 mm
for HIV uninfected participants. All participants were
evaluated by posterior-anterior chest radiograph with re-
sults detailed onto standardized case report forms by an
experienced radiologist. Treatment and diagnosis data
were abstracted from hospital records.
Study-related test results were communicated verbally
and in writing to treating clinicians. HIV-infected partici-
pants were referred to HIV Care and Treatment Centers
(CTC) either at KCMC Hospital, Mawenzi Regional Hos-
pital, or the CTC nearest to them. Outpatients, patients fit
for hospital discharge, and pediatric patients with positive
AFB smears and/or tuberculosis cultures were referred to
the National Tuberculosis Control Program, located at
Mawenzi Regional Hospital; but smear-positive patients
requiring ongoing hospitalization were referred to Kibon-
g’oto National Tuberculosis Hospital. The management of
patients with TB was the same regardless of site of enroll-
ment, however the follow up and management of patients
without confirmed TB was at the discretion of treating
clincians. Participants were seen for study visits 2 and
8 weeks after enrollment; those who did not attend ap-
pointments were traced by a field worker who came to
their homes, at which point vital status and tuberculosis
treatment status were ascertained. If no contact was made
by 12 weeks post enrollment into the study, the partici-
pant was considered lost to follow up.
Randomization
Randomization was stratified by age (adult ≥6 vs. child
<6) using simple randomization tables generated by
http://www.randomization.com. Randomization assign-
ments were pre-prepared in ordered, sealed envelopes to
be opened at the time that the participant’s first sputum
or GA sample arrived in the laboratory.
Laboratory procedures
Unconcentrated sputum and GA specimens from all par-
ticipants in both groups were first assessed by trained
laboratory technicians utilizing the Kinyoun modification
of the Ziehl-Neelson stain. Information about the pa-
tient’s clinical condition was not available to the labo-
ratory staff. For only the participants randomized to
intensified diagnostics, specimens were decontaminated
and centrifuged for concentration. Concentrated speci-
mens were then evaluated using both Kinyoun staining
and auramine-rhodamine fluorochrome staining with
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fluorescence microscopy. The intensified diagnostics group
also had all specimens inoculated into a bioMerieux BacT/
ALERT 3D Microbial Detection System. Mycobacterium
tuberculosis complex growth was confirmed with DNA
probe (AccuProbe Culture Identification Test MTB and
MAC kits, Gen-Probe Inc., San Diego, CA).
Diagnosis of tuberculosis and correct treatment
Participants who had at least one sputum smear positive
for acid-fast bacilli (concentrated or un-concentrated),
or at least one sputum or GA culture positive for MTB,
were considered to have were considered to have micro-
biologically confirmed tuberculosis.
Participants who did not have microbiologically con-
firmed tuberculosis were evaluated by a pediatric or adult
clinical endpoint committee (CEC) according to their age
group. Each committee had 2 Tanzanian clinicians and
one (pediatrics committee) or 2 (adult committee) U.S.
infectious disease specialists; all were experienced in TB
diagnosis. Committee members (who were not involved in
care of the participants) were provided with standardized,
de-identified clinical and radiographic data, including
chest radiograph images. Committee members independ-
ently characterized participants into 2 diagnostic categor-
ies (tuberculosis or not tuberculosis). Determination of
TB status was made by majority opinion among the CEC
members. Since there were 4 members in the adult com-
mittee, it was pre-determined that an even split among
the committee members on any one patient’s status would
result in random removal of all of the ratings of one of the
committee members.
Statistical analysis
We assumed that 80% of enrolled participants would truly
have tuberculosis [20-27], that 50% would be HIV-infected
[28,29], and that the sensitivity of un-concentrated AFB
smear for pulmonary TB was 38% in HIV-uninfected per-
sons and 29% in HIV-infected persons (respective sensi-
tivities of 50% and 38% were assumed for concentrated
smears). Assuming 90% of intensified arm participants and
65% of standard arm participants will have been correctly
prescribed therapy by 8 weeks, these assumptions would re-
sult in correct therapy (either anti-TB in the case of TB or
no anti-TB in the case of no TB) for 93% of participants in
the intensified diagnostic arm vs. 73% of participants in the
standard arm (e.g. a participants in the standard arm (e.g. a
25% relative increase). A sample size of 120 (60 participants
in each arm) was planned in order to afford at least an 80%
power to detect an absolute difference of 20% in appropri-
ate therapy between the 2 groups with a one sided Fisher’s
exact test at the level of 0.025 significance.
Data were entered utilizing an automated Verity® Tele-
form® data entry system (Verity, Pleasonton, CA) into a
Microsoft Access 2003 database; missing values or those
which lay outside of anticipated ranges were re-checked
for quality and manually entered as appropriate.
Participants who had microbiologically or clinically
confirmed TB were considered to be correctly treated if
they had initiated multi-drug anti-TB therapy and con-
tinued through their last study visit. Those for whom TB
had been excluded on both clinical and microbiologic
grounds who were not receiving anti-TB therapy were
also considered to be correctly treated. All others were
considered to be incorrectly treated. The primary endpoint
was correct treatment at 8 weeks for patients who were
alive and had 8-week follow-up data. Pre-specified second-
ary analyses included an assessment of correct treatment
among those with smear-negative, culture-positive TB at
2 weeks, impact of specimen concentration on sensitivity
and specificity among adults and children, and differences
between HIV-infected and uninfected participants. All
other statistical testing was post hoc, and assessment of
association with mortality was explored carefully based on
the somewhat unexpected high proportion of mortality.
P-values were calculated using one-sided Fisher’s exact
tests, and were not adjusted for multiple comparisons.
Survival was assessed using Kaplan-Meier curves, and
between-group differences were assessed with the log-
rank test.
Ethical considerations
The study was approved by the Kilimanjaro Christian
Medical College Ethical Committee, the Tanzania National
Institutes for Medical Research Ethical Coordinating Co-
mmittee, and the Duke University Medical Center Institu-
tional Review Board. The study has been registered with
the Pan African Clinical Trials Registry (www.pactr.org)
with the registry number PACTR201402000765312.
Results
3,249 patients were screened for eligibility, 358 (11.2%)
met clinical criteria for suspect tuberculosis, and 70 were
enrolled (Figure 1 and Table 1). Enrollment was curtailed
with the end of project funding, limiting the number of
potentially eligible participants screened and enrolled.
Sixty-five (92.9%) participants provided at least 2 spu-
tum or GA specimens. Direct (unconcentrated) sputum or
GA smears for AFB were positive in 11 (15.7%) (6 HIV-
infected and 5 HIV-uninfected), and culture was positive
for Mycobacterium tuberculosis in an additional 6 (18.2%)
of 33 participants in the intensified arm, for a total of 17
(24.3%) participants with microbiologically confirmed tu-
berculosis. Concentrated smear detected AFB in 4 samples
which were direct smear negative; the sensitivity of con-
centrated smear was 42.8% and of direct smear was 32.1%.
In addition to the 17 participants with positive AFB
smears and/or TB cultures, 14 participants [4 (20.0%)
children and 10 (29.4%) adults, p = 0.51] without a
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Figure 1 CONSORT diagram.
Table 1 Baseline characteristics of 70 patients with suspect tuberculosis, Tanzania, 2008–9, by age and randomization
group, n(%) or median (intraquartile range)
Age ≥6 years Age <6 years
All Standard Intensified Standard Intensified Standard Intensified
All 70 37 33 27 (57) 20 (43) 10 (43) 13 (57)
Female 35 21 (57) 14 (42) 14 (52) 9 (45) 7 (78) 5 (42)
Age (years), participants ≥6 years 37 (28–48) 37 (28–48) 37 (30–46) 38 (29–50) 38 (31–46) n/a n/a
Age (months), participants <6 years 16 (6–22) 21 (5–47) 11 (6–19) n/a n/a 21 (5–47) 10.5 (6–18)
Enrolled from outpatient 4 (6) 1 (3) 3 (9) 1 (4) 3 (15) 0 0
Days ill prior to enrollment 21 (16–60) 30 (20–60) 21 (14–44) 45 (30–60) 21 (14–60) 14 (12–17) 20 (14–36)
Fever 52 (74) 27 (73) 25 (76) 19 (70) 13 (65) 8 (80) 12 (92)
Cough 68 (97) 35 (95) 33 (100) 27 (100) 19 (95) 9 (90) 13 (100)
Weight loss 45 (64) 22 (60) 23 (70) 17 (63) 16 (80) 5 (50) 7 (54)
Night sweats 21 (30) 10 (27) 11 (33) 10 (37) 6 (20) 1 (10) 4 (31)
Clinical suspicion extrapulmonary TB 3 (4) 2 (5) 1 (3) 2 (7) 1 (5) 0 0
Chest radiograph suspect TB*† 31 (50) 19 (51) 12 (41) 15 (56) 9 (45) 3 (30) 4 (30)
Chest infiltrates, no other suspicious features 19 (31) 8 (24) 11 (38) 4 (15) 5 (20) 7 (60) 3 (23)
Previously treated for TB 4 (6) 3 (8) 1 (3) 3 (11) 1 (5) 0 0
Malnourished** 39 (56) 20 (54) 19 (58) 15 (56) 11 (55) 5 (50) 8 (62)
HIV infection 34 (49) 15 (41) 19 (58) 13 (48) 13 (65) 2 (20) 6 (46)
<12 months since HIV diagnosis†‡ 28 (82) 15 (100) 13 (68) 8 (30) 13 (100) 1 (50) 5 (83)
Antiretroviral therapy at enrollment† 13 (38) 5 (33) 8 (42) 4 (15) 7 (35) 1 (50) 1 (17)
CD4+ cell count/mm3‡ 180 (10–405) 172 (17–293) 180 (9–578) 172 (15–291) 19 (8–229) n/a n/a
CD4+ cell percentage‡ 0.9 (0.2–16) 0.5 (0.2–21) 0.9 (0.2–16) n/a n/a 23 (0.5-45) 16 (8–30)
*Presence of cavitation, micronodules, pleural effusion with infiltrate, or infiltrate pattern suspicious for TB as per radiologist.
**Body mass index <20 or weight for height >2 standard deviations below mean.
†Percentages of those with available data.
‡Among HIV infected.
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microbiological diagnosis of TB were diagnosed with
clinical TB by the CEC. Therefore, a total of 31 (44.3%)
participants had a final diagnosis of TB.
Forty-seven participants were alive and in follow up to
be assessed for the primary endpoint of treatment at
8 weeks (Table 2). All patients in the intensive arm
(100%; n = 22) were receiving correct care vs. 22 (88.0%)
of the 25 participants in the standard arm (p = 0.14). In
the standard arm all 9 patients determined to have clin-
ical or microbiologically confirmed TB were receiving
anti-TB medications but 3 (18.8%) of 16 patients deter-
mined not to have TB by the CEC were continuing anti-
TB medications. All participants with smear positive TB
who were alive at 8 weeks were correctly receiving anti-
TB medications.
Six participants were AFB smear negative and TB cul-
ture positive. While 4 (66.7%) of these were culture posi-
tive prior to the 2 week visit, 3 of the 4 died prior to or
within 72 hours of receipt of culture results and were
never started on anti-TB medications, and the other was
empirically started on anti-TB medications prior to cul-
ture results. The remaining 2 participants, whose cul-
tures became positive after the 2 week visit, were started
on anti-TB medications after receipt of culture results.
In a post hoc analysis of all participants utilizing last
available treatment status prior to death or loss to follow
up, participants in the intensified arm were more likely
to receive correct care than participants in the stand-
ard arm [29 (87.9%) of 33 vs. 26 (70.3%) of 37; OR 3.1,
p = 0.06]. This trend was also noted among smear-
negative participants (24 (88.9%) of 27 received correct
treatment in the intensified arm vs. 21 (65.6%) of 32 in
the standard arm; OR = 4.1, p = 0.04]. Among 4 partici-
pants in the intensified arm and 11 participants in the
standard arm who were treated incorrectly, 12 were
not receiving anti-TB medication when it would have
been recommended by the CEC, and 3 were receiving
anti-TB medication when it would not have been
recommended.
In a post hoc analysis of mortality, 18 (25.7%) of the
70 participants died during the study period at a me-
dian of 14 (IQR 7.8-26) days after enrollment, and an
additional 7 (10.0%) participants were lost to follow up.
The median time to death was 13.5 days (IQR 8,24). All
of the patients who died were initially enrolled in the
inpatient setting. No direct association was detected
between death and assignment to standard or intensive
diagnostics, presence of smear positivity, age group,
nor days of illness prior to enrollment. Mortality was
also not significantly associated with HIV status among
all patients; for patients with HIV, death was not asso-
ciated with severity of immune suppression or use of
antiretroviral therapy.
Receipt of anti-TB medications was inversely associ-
ated with death (OR 0.2, p = 0.04; see Table 3, Figure 2)
in the cohort as a whole and among HIV-infected partic-
ipants and adults; HIV-infected participants who re-
ceived anti-TB were significantly less likely to die than
Table 2 Odds of correct care* by randomization group among 70 patients with suspect tuberculosis, Tanzania, 2008-9
Standard diagnostics Intensified diagnostics OR (CI) p
Correct care at 8 weeks (for living participants in follow up; n = 47)
n for group n correct care % correct care n for group n correct care % correct care
All participants 25 22 (88) 22 22 (100) Undefined 0.14
TB+ 9 9 (100) 9 9 (100) 1
TB- 16 13 (81) 13 13 (100) Undefined 0.15
Smear negative
participants
20 17 (85) 19 19 (100) Undefined 0.12
TB+ 4 4 (100) 6 6 (100) 1
TB- 16 13 (81) 13 13 (100) Undefined 0.15
Correct care censored at death or last study visit; n = 70
n for group n correct care % correct care n for group n correct care % correct care
All participants 37 26 (70) 33 29 (88) 3.1 (0.87,10.8) 0.06
TB+ 16 9 (56) 16 11 (69) 2.1 (0.47, 9.7) 0.27
TB- 21 17 (81) 18 18 (100) Undefined 0.07
Smear negative
participants
32 21 (66) 27 24 (89) 4.2 (1.0,17.1) 0.04
TB+ 11 4 (36) 9 6 (67) 3.5 (0.55, 22.3) 0.18
TB- 21 17 (81) 18 18 (100) Undefined 0.07
*Defined as TB therapy if designated to have clinically (by clinical endpoint committee) or microbiologically diagnosed TB, or no TB therapy if determined not to
have TB.
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those who didn’t (OR undefined, p = 0.01) as were adults
who received anti-TB compared with those who didn’t
(OR 0.19, p = 0.02). Six (35.3%) of 17 patients with micro-
biologically confirmed TB died, 5 of whom never received
anti-TB medications. Of these 5 who had microbiologic-
ally confirmed TB but never received medications, 4 died
within 3 days of the first positive sputum or gastric aspir-
ate specimen, and 1 died 10 days after return of the first
positive gastric aspirate specimen. Four of the 5 were en-
rolled from KCMC, the tertiary referral hospital, where
anti-TB is not available on-site. Of the 11 patients who
died without a microbiologically confirmed diagnosis of
Table 3 Associations with death and receipt of antituberculous treatment among 70 participants with suspect
tuberculosis Tanzania, 2008-9
All Anti-TB No anti-TB OR p
All 70 22 (31)*† 48 (68)
Death before 2 weeks 9 (13) 1 (4) 8 (17) 0.25 (0.03–2.0) 0.25
Any death 18 (26) 2 (9) 16 (33) 0.2 (0.04–0.96) 0.04
Pediatric 23 7 (30) 16 (69)
Death before 2 weeks 2 (9) 1 (14) 1 (6) 2.5 (0.13–46.8) 0.53
Any death 4 (17) 1 (14) 3 (19) 0.72 (0.06–8.5) 0.66
Adult 47 15 (32) 32 (68)
Death before 2 weeks 7 (15) 0 7 (22) undefined 0.08
Any death 14 (30) 1 (7) 13 (41) 0.10 (0.01–0.89) 0.02
HIV-infected 34 10 (29) 24 (71)
Death before 2 weeks 5 (15) 0 5 (21) undefined 0.29
Any death 9 (26) 0 9 (38) undefined 0.01
Smear-negative 59 13 (22) 46 (78)
Death before 2 weeks 7 (12) 0 7 (15) undefined 0.33
Any death 15 (25) 1 (8) 14 (30) 0.19 (0.02–1.6) 0.15
Standard arm 37 12 (32) 25 (68)
Death before 2 weeks 4 (11) 0 4 (19) undefined 0.19
Any death 9 (24) 1 (8) 8 (32) 0.19 (0.05–1.5) 0.12
Intensified arm 33 10 (30) 23 (70)
Death before 2 weeks 5 (15) 1 (10) 4 (17) 0.53 (0.20–1.4) 0.29
Any death 9 (27) 1 (10) 8 (35) 0.20 (0.00–1.4) 0.15
*An additional 2 patients were prescribed anti–TB but died before initiating therapy.
†Percentages refer to proportion of total in each category.
p–values in bold are statistically significant at a level of p<0.05.
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TB and did not receive anti-TB, 9 died with a diagnosis of
pneumonia and/or HIV/AIDS.
Discussion
The impact of intensified microbiologic testing on TB
management in our study was attenuated by a strikingly
high mortality rate, even among HIV-negative subjects.
More than one quarter of the study participants died
prior to the end of the 8 week study period, including a
third of the patients with microbiologically confirmed
tuberculosis; this parallels or exceeds mortality seen in
case series of patients with TB in other high-burden,
HIV-prevalent settings [14-16,30]. Mortality was seen in
all major subgroups, including HIV infected and unin-
fected participants and children as well as adults. Enroll-
ment primarily from the wards of a tertiary referral
hospital surely contributed to these findings, and they
underscore the ongoing challenges for providing quality,
accessible primary health care in a resource-limited set-
ting. Five of those with confirmed TB died prior to initi-
ation of anti-TB; in 4 of these 5 cases, results were
available only after death or within 72 hours prior to
death. Most importantly, these results suggest that better
diagnostic testing at tertiary care centers in developing
world settings are unlikely to change outcomes without
measures to improve access to such testing among per-
sons in the community, and/or community awareness of
the importance of early presentation with symptoms
possibly compatible with TB. While late diagnosis was
likely the major contributor to mortality in this cohort,
it is important to note that anti-TB medications are not
always immediately available to clinicians in our setting.
For example, anti-TB medications must be dispensed
from the regional TB office adjacent to Mawenzi Re-
gional Hospital during weekdays only. While it is not
clear that earlier receipt of anti-TB by a few days in crit-
ically ill patients would have been life-saving, it may
have been; means to ensure more rapid receipt of anti-
TB in emergency cases have been considered and on-
going discussions are in progress.
Despite the overarching message of our data that TB
needs to be considered and empiric therapy may save
lives, overtreatment was noted in our study and formed
the major difference between the standard and intensive
groups in terms of the primary endpoint of correct treat-
ment at 8 weeks. The lack of ability to obtain cultures
and/or molecular diagnostics may result in both overtreat-
ment as well as under treatment of TB, possibly leading
the clinician away from consideration of other diagnoses
and exposing patients to medication toxicity [31,32].
In addition, 10% of our cohort was lost to follow up des-
pite obtaining contact information and attempts to reach
them by a field worker. One-third of smear negative
participants in the intensified arm were culture positive.
While we worked closely with the National TB Control
Program to contact the 2 culture-positive participants
who were not already being treated, tracking down
smear-negative, culture-positive persons after they have
left initial care will require significant resources that
may not be available, again underscoring the import-
ance of rapid diagnostics.
Our study has several important limitations, including
being underpowered due to a lengthy regulatory process
and subsequent delays in enrollment, a substantial pro-
portion of symptom-eligible patients excluded on other
grounds, and the lack of a gold standard diagnosis. The
latter was mitigated by the use of the CEC.
Despite these limitations, to our knowledge this is the
first study to use a prospective, randomized approach
to examine the clinical benefit of the addition of TB cul-
ture to smear microscopy alone in a resource limited
settings, where to date implementation of culture to
improve diagnosis remains slow.
Conclusions
Our data suggest that access to more sensitive TB diag-
nostics is associated with more appropriate therapy, both
for those with and without TB. The high mortality seen
in our study, present across all age groups and among
patients with and without HIV, points to the need for
operational studies coupling earlier access to care with
intensified diagnostics for TB suspects.
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